Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity.

Tofacitinib is an orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities.

WP1066 is a novel inhibitor of JAK2 and STAT3.

TG101209 is a selective JAK2 inhibitor.

Gandotinib (LY2784544) is a potent JAK2 inhibitor.

AZD1208 is a potent, and orally available Pim kinase inhibitor.

Roxadustat is an orally bioavailable, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), with potential anti-anemic activity.

2-Methoxyestradiol is an orally bioavailable estradiol metabolite with potential antineoplastic activity.